Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Diarrhea 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Low Anterior Resection Syndrome 1Colitis 1

Interventions

pembrolizumab 5fludarabine 2enfortumab vedotin 2darolutamide 2atezolizumab 2aldesleukin 2Riluzole 2Nivolumab 2Mitomycin 2Fecal Microbiota Transplantation 2Cyclophosphamide 2vedolizumab 1relatlimab 1prednylidene 1olaparib 1lenvatinib 1deltacortene 1cabozantinib 1Watchful Waiting 1Transurethral Resection of Prostate 1Tadalafil 1Surveys and Questionnaires 1Standard of Care 1Specimen Handling 1Rivaroxaban 1Radiosurgery 1Radiation Dose Hypofractionation 1Pregnancy Tests 1Prednisone 1Practice Guidelines as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Urogenital Neoplasms × Loperamide × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡